Granted Patent B2

US 12,643,949 · App. 18/351,184 · Granted Jun 2, 2026

Inventors: Isaac J. Rondon (Emeryville, CA); Christine Janson (Emeryville, CA); Manankumar Anilkumar Shah (Emeryville, CA); Karin Jooss (San Diego, CA)

Assignee: Gritstone bio, Inc.

C07K16/2833A61P35/00C07K16/2809C07K16/468A61K2039/505C07K2317/31C07K2317/622C07K2317/626C07K2317/732C07K2317/92C07K2317/94

Abstract

Claims (25)

1 . An isolated antigen binding protein (ABP) that comprises:

a first antigen binding region (ABR) and a second ABR that each specifically bind a first target antigen, a Fab that specifically binds a second target antigen CD3, and an Fc domain, wherein the ABP comprises a first polypeptide, a second polypeptide, and a third polypeptide; wherein the first polypeptide comprises, in an N→C direction, the first ABR-a first hinge-CH2-CH3; wherein the second polypeptide comprises, in an N→C direction, the second ABR-a variable heavy chain (VH) domain of the Fab-a CH1 domain of the Fab-a second hinge-CH2-CH3; wherein the third polypeptide comprises, in an N→C direction, a variable light chain (VL) domain of the Fab-a CL domain of the Fab;

wherein the first ABR and second ABR each comprise, in an N→C direction: (i) a VH domain-a VL domain or (ii) a VL domain-VH domain;

wherein the VH domain of the first ABR is attached to the VL domain of the first ABR via a first linker;

wherein the VH domain of the second ABR is attached to the VL domain of the second ABR via a second linker;

wherein the first linker and second linker are each about 5-15 amino acids in length; and

wherein the first target antigen is an HLA-PEPTIDE target comprising an HLA-restricted peptide complexed with an HLA Class I molecule, wherein the HLA Class I molecule is HLA subtype HLA-A*01:01 and the HLA-restricted peptide comprises the sequence NTDNNLAVY (SEQ ID NO: 214); and

wherein the VH domains of the first and second ABRs each comprise complementarity-determining regions (CDR)-H1, CDR-H2, and CDR-H3 comprising the sequences set forth in SEQ ID NOS: 18, 19, and 20, respectively and wherein the VL comprises CDR-L1, CDR-L2, and CDR-L3 comprising the sequences set forth in SEQ ID NOS: 21, 22, and 23, respectively.

2 . The isolated ABP of claim 1 , wherein the first linker and second linker are each individually 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-15, 9-14, 9-13, 9-12, 9-11 or 9-10 amino acids in length.

3 . The isolated ABP of claim 1 , wherein the VH and VL domains of the Fab comprise CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprising the sequences set forth in SEQ ID NOS: 36, 37, 38, 39, 40, and 41; 26, 27, 28, 29, 30, and 31; or 42, 43, 44, 45, 46, and 47 respectively.

4 . The isolated ABP of claim 1 , wherein the VH of the first and second ABRs comprises the sequence set forth in SEQ ID NO: 6 and wherein the VL of the first and second ABR comprises the sequence set forth in SEQ ID NO: 4.

5 . The isolated ABP of claim 1 , wherein the VH and VL of the Fab comprises the sequence set forth in SEQ ID NOS: 32 and 33; 24 and 25; or 34 and 35, respectively.

6 . The isolated ABP of claim 1 , wherein the first polypeptide comprises the sequence set forth in SEQ ID NO: 55 or the sequences set forth in SEQ ID NO: 55 and 48.

7 . The isolated ABP of claim 1 , wherein the second polypeptide comprises the sequence set forth in SEQ ID NOs: 55 or the sequences set forth in SEQ ID NOs: 55 and 51, 49, or 53.

8 . The isolated ABP of claim 1 , wherein the third polypeptide comprises the sequence set forth in SEQ ID NOs: 52, 50, or 54.

9 . The isolated ABP of claim 1 , wherein the first polypeptide comprises the sequence set forth in SEQ ID NO: 55 and 48, the second polypeptide comprises the sequence set forth in SEQ ID NO: 55 and 51, and the third polypeptide comprises the sequence set forth in SEQ ID NOs: 52.

10 . The isolated ABP of claim 1 , wherein the VL domain of the first ABR interacts with the VH domain of the second ABR and wherein the VH domain of the first ABR interacts with the VL domain of the second ABR.

11 . The isolated ABP of claim 1 , wherein the antigen binding protein is linked to a scaffold, optionally wherein the scaffold comprises serum albumin or Fc, optionally wherein Fc is human Fc and is an IgG (IgG1, IgG2, IgG3, IgG4), an IgA (IgAQ1, IgA2), an IgD, an IgE, or an IgM.

12 . The isolated ABP of claim 1 , comprising a variant CH2-CH3 domain, wherein the variant CH2-CH3 domain of the first or second polypeptide comprises a knob-in-hole modification.

13 . An isolated polynucleotide or set of polynucleotides encoding the antigen binding protein of claim 1 or an antigen-binding portion thereof.

14 . A vector or set of vectors comprising the polynucleotide or set of polynucleotides of claim 13 .

15 . A host cell comprising the polynucleotide or set of polynucleotides of claim 13 , optionally wherein the host cell is CHO or HEK293, or optionally wherein the host cell is a T cell.

16 . A method of producing an antigen binding protein comprising expressing the antigen binding protein with the host cell of claim 15 and isolating the expressed antigen binding protein.

17 . A pharmaceutical composition comprising the antigen binding protein of claim 1 and a pharmaceutically acceptable excipient.

18 . A method of increasing an immune response in a subject, comprising administering to the subject the ABP of claim 1 , optionally wherein the subject has cancer.

Assignments (1)

Continuity (3)

References Cited (400)